|
The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has sought inputs and comments from member pharma exporters for review of Remission of Duties and Taxes on Exported Products (RoDTEP) scheme and Rebate of State and Central Taxes and Levies (RoSCTL) rates framed by the RoDTEP Committee 2025.
The Government of India (GoI) has constituted a Committee in 2025 to review and update the ceiling rates for the RoDTEP and the RoSCTL schemes.
“The Committee adopted a draft data submission format for trade stakeholders and is seeking suggestions on this format by October 24, 2025, with a proposed data period from April 1, 2024, to March 31, 2025. Additionally, the Committee plans to hold a stakeholder consultation, with scheduling details to be communicated later. The member exporter companies have been urged to provide the inputs in a specified format and can send the same by October 23, 2025 at dgdesk@pharmexcil.com,” informed Raja Bhanu, director general, Pharmexcil.
The Union ministry of commerce & industry had officially extended the RoDTEP Scheme till March 31, 2026 through a notification dated September 30, 2025 issued by the Directorate General of Foreign Trade (DGFT), under the authority of the Foreign Trade (Development and Regulation) Act, 1992, and the provisions of the Foreign Trade Policy (FTP) 2023.
The RoDTEP Scheme, which was earlier set to expire on September 30, 2025, will now continue to apply to exports from Domestic Tariff Area (DTA) units, Advance Authorisation (AA) holders, Special Economic Zone (SEZ) units, and Export Oriented Units (EOUs) until the end of the current financial year.
The extension ensures that pharma exporters continue to receive remission of embedded central, state, and local duties and taxes. These include taxes on electricity, fuel, and logistics services, which are often non-recoverable and add to the cost burden for exporters.
The DGFT has confirmed that existing RoDTEP rates and item eligibility will remain unchanged. Exporters can refer to the official website of DGFT (www.dgft.gov.in) under the section “Regulations > RoDTEP” for detailed lists of eligible items along with applicable rates and per-unit value caps. These are separately listed in Appendix 4R for DTA units and Appendix 4RE for AA, SEZ, and EOU units.
The existing RoDTEP rates, as notified, shall continue to apply for all export items. The operation of the scheme shall, however, remain subject to the budgetary framework provided under Para 4.54 of FTP 2023, so that the remissions during the financial year are managed within the approved allocation.
Extension of RoDTEP will lead towards enhancing the global competitiveness of Indian pharma exports by reducing the burden of taxes. It is especially timely as exporters navigate a dynamic global trade environment marked by shifting supply chains, evolving market demands, and recovery from recent global disruptions.
Pharma exporters and industry stakeholders have welcomed the extension, calling it a positive step towards maintaining policy stability and boosting India’s foreign trade prospects in the near term.
|